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Emergence of castration-resistant metastatic prostate cancer is due to activation of survival pathways, including apoptosis sup-
pression and anoikis resistance, and increased neovascularization. Thus targeting of apoptotic players is of critical significance 
in prostate cancer therapy since loss of apoptosis and resistance to anoikis are critical in aberrant malignant growth, metastasis 
and conferring therapeutic failure. The majority of therapeutic agents act through intrinsic mitochondrial, extrinsic death receptor 
pathways or endoplasmic reticulum stress pathways to induce apoptosis. Current therapeutic strategies target restoring regulatory 
molecules that govern the pro-survival pathways such as PTEN which regulates AKT activity. Other strategies focus on reactivat-
ing the apoptotic pathways either by down-regulating anti-apoptotic players such as BCL-2 or by up-regulating pro-apoptotic 
protein families, most notably, the caspases. Caspases are a family of cystine proteases which serve critical roles in apoptotic and 
inflammatory signaling pathways. During tumorigenesis, significant loss or inactivation of lead members in the caspase family leads 
to impairing apoptosis induction, causing a dramatic imbalance in the growth dynamics, ultimately resulting in aberrant growth 
of human cancers. Recent exploitation of apoptosis pathways towards re-instating apoptosis induction via caspase re-activation 
has provided new molecular platforms for the development of therapeutic strategies effective against advanced prostate cancer 
as well as other solid tumors. This review will discuss the current cellular landscape featuring the caspase family in tumor cells and 
their activation via pharmacologic intervention towards optimized anti-cancer therapeutic modalities. This article is part of a Spe-
cial Issue entitled “Apoptosis: Four Decades Later”.
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THE CHALLENGE IN CANCER TREATMENT 
In the year ����� the challenge for clinicians� onco­
lo gists and �asic scientists remains the development 
of effective therapeutic strategies that �lock malignant 
cell growth� without impairing normal healthy cells. 
Investigative efforts focus on successful exploitation 
of cancer specific characteristics acquired during 
malignant transformation via a series of genetic and 
epigenetic mutations resulting in uncontrolled growth 
and evasion of apoptosis mechanisms [�]. Losing 
critical regulatory mechanisms that control normal 
tissue homeostasis ena�les tumor cells to acquire 
new characteristics such as tissue invasion� metasta­
sis and angiogenesis. �ome of the control pathways 
are activated such as cell proliferation� cell cycle pro­
gression and pro­survival pathways� while others are 
down­regulated� like the cell death pathways including 
apoptosis and anoikis. 
A�errant cell proliferation during cancer initiation 
and progression to metastasis is controlled �y cell 
cycle progression. The cell cycle consists of several 
phases; G�� G�� �� G�� and Mitosis regulated �y vari­
ous cyclins and CDK �cyclin dependant kinases� and 
progression from one phase to another is dependent 
on specific checkpoints [�]. A very critical player at this 
checkpoint is p�� �notoriously known as the guardian 
of the genome� due to its role in rescuing damaged 
DNA� via up­regulation of downstream effectors� such 
as p�� �induces cell cycle arrest� and PUMA which 
�locks anti­apoptotic players leading to apoptosis 
induction [�]. Cell cycle regulation via p�� can prima­
rily �e a�rogated �y loss­of­function mutations� losing 
p�� activity allows for the cell to replicate regardless 
of DNA integrity and increases apoptosis resistance 
[�]. Additional mechanisms of p�� down­regulation 
involve the over­expression of MDM�� an E� ligase 
that mediates the polyu�iquitination of p�� resulting 
in its degradation. Over­expression of MDM� ensures 
rapid degradation of p�� leading to diminished if not 
a�olished p�� activity and unregulated cell cycle 
progression [�]. Proteasome inhi�itors� agents that 
�lock protein degradation mediated �y ��� protea­
some� have �een shown to sta�ilize p�� and restore 
p�� mediated apoptosis [�]. Esta�lished chemo­
therapeutic agents such as mitomycin C or doxoru­
�icin are used to induce cell cycle arrest in a variety 
of epithelial cancers. These agents work to either 
cross link DNA �mitomycin C� or �ind directly to the 
DNA intercalating into the dou�le­helix strands caus­
ing the DNA to �ecome rigid and �reak �doxoru�icin� 
[�]. The major limitation however is that these drugs 
damage surrounding healthy normal cells� tissues� 
and organs such as kidney �mitomycin C� or the heart 
�doxoru�icin� [8� 9]. Treatment of MCF­� �reast cancer 
xenografts with a com�ination of mitomycin C with 
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curcumin significantly decreased mitomycin C related 
side effects [��]. 
�trategies involved with overcoming the toxic 
side effects of doxoru�icin �y changing the mode 
of doxoru�icin delivery �y encapsulating the drug 
in titanium nanoparticals which showed promising 
results [��]. Circumventing the caveats associated 
with systemic toxicities of these chemotherapeutics 
involved examining other pro­survival pathways� such 
as the AKT signaling pathway which can also impact 
cell cycle regulation and growth arrest. The AKT path­
way is activated through �inding of growth factors 
to their cognate tyrosine kinase receptors which then 
carry out the signal transduction through the interplay 
�etween �RC� phosphatidylinositol­� kinase �PI�K� 
and phosphotidylinositol­�� �­�isphosphate �PIP��� 
and phosphotidylinositol­�� �� �­triphosphate �PIP�� 
and a critical regulatory molecule� PTEN [��]. PTEN� 
a phosphatase� regulates AKT activation �ecause 
it dephosphorylates and converts PIP� to PIP� thus 
preventing PIP��AKT interaction [��]. AKT is a kinase 
that phosphorylates several different targets such 
as mTOR� IKK �an inhi�itory �inding protein that pre­
vents the nuclear factor of kappa B �NF­κB� activation�� 
and cell cycle inhi�itors �p��� p���. In cancer activation 
of the AKT pathway can �ecome a�errant �ecause 
of a variety of mutations that can occur within PI3K� 
AKT� and PTEN [��]. One of the most detrimental and 
oncogenic potential promoting mutations are those 
that render these molecules constitutively active. Con­
stitutively active PI�K can lead to the increase in the 
conversion rate of PIP� to PIP� favoring PIP� produc­
tion leading to increased AKT activation [��]. A spe­
cific AKT mutation� E��K in either AKT� or AKT� leads 
to constitutive activation and promotes increased 
trafficking to the plasma mem�rane [��]. PI3K and 
AKT activating mutations are deleterious for the cell; 
however� another mechanism that can elevate AKT 
activity to supra­physiological levels and contri�ute 
to oncogenesis is the loss of PTEN� a critical regula­
tor of AKT activation. Interrogation of the signaling 
events dictated �y AKT� mTOR� and PI�K has lead to the 
development of a powerful class of pharmacologic 
inhi�itors. The most promising class of AKT inhi�itors 
are the lipid �ased inhi�itors which essentially inhi�it 
AKT �inding to the plasma mem�rane. Perifosine has 
emerged as one of the most promising AKT inhi�itors 
and has �een through several phase II clinical tri­
als [����9]. The mTOR inhi�itors include rapamycin 
and its derivatives� such as CCI­��9� �locks mTOR 
function through similar mechanisms that primarily 
involve �inding to the co­factor FKBP and together� 
rapamycin and FBKP �ind to mTOR and inhi�it activity 
[��]. PI�K inhi�itors like wortmannin or its derivative� 
LY�9���� �ind covalently to PI�K to inhi�it its kinase 
activity [��]. These agents however� lack specificity 
and new carefully designed inhi�itors such as CAL­
��� �Calistoga� have shown promising results in clini­
cal trials [��] which are on­going at Clearview Cancer 
institute ������. PI�K inhi�itors exhi�it higher efficacy 
com�ination with existing chemotherapeutic agents 
such as� an AKT or mTOR inhi�itors �ecause these 
com�inations �lock two pathways� eliminating indi­
vidual pathway activity as well as preventing activation 
of alternate or redundant non­AKT mediated pathways 
activated through PI�K [��]. PTEN is the direct inhi�i­
tor of AKT �ecause it converts AKT activating PIP� into 
PIP�� which does not activate AKT. PTEN studies have 
revealed that PTEN may �e down­regulated either 
through inactivating mutations� gene deletions� and 
phosphorylation of PTEN �y CK� have the same result� 
persistent AKT signaling that contri�utes to tumor 
formation [��]. PTEN loss has �een associated with 
several cancers at the advanced stage of disease� 
including prostate cancer [��]. PTEN mutations have 
�een linked with aggressive androgen dependant 
or androgen independent �termed castration recur­
rent� prostate cancer [��� ��] and evidence suggests 
that oncogenesis results due to the loss of AKT and 
cell cycle regulation [��� �8].
Prostate cancer is one of the most prevalent 
causes of cancer related death in males with several 
risk factors� such as age� race� and diet contri�uting 
towards prostate cancer development and progression 
[�9]. Regulation of androgen signaling via the andro­
gen receptor �AR� is critical to maintaining prostate 
homeostasis. The androgen axis involves conver­
sion of testosterone into �α­dihydrotestosterone 
�y �α­reductase� the active meta�olite that �inds 
to AR and the ligand­receptor complex is translocated 
to the nucleus to activate su�sequent signaling path­
ways [��]. When prostate cells undergo tumorgenesis 
they take on different molecular characteristics� one 
of the more prominent changes is the up­regulation 
of androgen receptor either through gene amplifica­
tion or through other processes leading to AR over­
expression [��]. �uch an event prominently activates 
AR pathways leading to increased proliferation and 
reduced apoptosis� or may further sensitize prostate 
cancer cells to growth factors stimuli such as EGFR 
[��]. Currently the most promising therapy for treating 
castration­recurrent prostate cancer �CRPC�� involves 
chemically depleting androgens in the prostate �y in­
hi�itors of androgen axis such as a�iraterone [��]. 
Additional agents are currently �eing tested in clinical 
trials such as MDV���� which is a competitive inhi�i­
tor �locking AR�androgen signaling with therapeutic 
promise in prostate cancer patients [��].
Another class of chemotherapeutics are protea­
some inhi�itors capa�le of inducing apoptosis and thus 
with great potential as anti­cancer agents [��]. There 
are two types of proteasome inhi�itors� natural inhi�i­
tors �lactacystin and epoxomicin� and synthetic inhi�i­
tors such as MG��� and velcade [��]. MG��� inhi�its 
the chymotrypsin like activity of the ��� proteasome 
[��]. Velcade� �P�­���/�ortizomi�� is an FDA ap­
proved proteasome inhi�itor used in treating multiple 
myeloma [�8]. Velcade is a dipeptide �oronic acid 
small molecule that �locks the chymotrypsin­like 
activity of the ��� particle [�9]. Investigators have 
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reported that velcade has an impact on several key 
cellular processes such as inhi�iting cell cycle and 
NF­κB activation [��]. Velcade sensitizes cancer 
cells to apoptosis through several mechanisms� such 
as the down­regulation of c­FLIP� which inhi�its cas­
pase­8 activation at the DI�C [��]. �everal in vitro 
and in vivo studies have shown that velcade induces 
apoptosis in multiple myeloma cells [��]. However 
multiple myeloma patients are either initially resistant 
or acquired resistance to velcade during the course 
of treatment [��]. Attempts to overcome velcade 
resistance have led to development of various com­
�inations of velcade with different chemotherapeutic 
agents such as� PCI­���8� �an HDAC inhi�itor� which 
was found to synergize with velcade to induce reactive 
oxygen species damage as well as caspase­8 activa­
tion in non­Hodgkins lymphoma [��]. �ignificantly 
enough� Mitsiades and colleagues [��]� showed that 
velcade in com�ination with doxoru�icin can overcome 
velcade resistance in multiple myeloma. Another anti­
cancer strategy involved using velcade in com�ination 
with TNF­α related apoptosis inducing ligand �TRAIL�. 
Recent studies �y Christian et al. suggests the a�ility 
of velcade to sensitize TRAIL­resistant prostate can­
cer cell lines in vitro and in vivo to TRAIL­mediated 
apoptosis and together TRAIL and velcade sta�ilize 
caspase­8 p�8 su�unit [��� ��]. 
A major caveat for using velcade as an anti­cancer 
strategy is the lack of cell type and cell signaling 
specificity. Velcade was designed to �lock the protea­
some and not to discriminate �etween a malignant 
or a healthy cell therefore� all cells are impacted �y vel­
cade treatment. Velcade treatment can lead to side 
effects such as throm�ocytopenia and peripheral 
neuropathy [�8]. To �ypass the caveats associated 
with velcade� while achieving apoptosis induction 
investigators are pursuing the activity of E� ligases 
in an attempt to achieve and their involvement with 
the extrinsic pathway of apoptosis. 
For CRPC� taxanes provide the only clinically ef­
fective chemotherapeutic approach. These agents 
target microtu�ules and the cellular cytoskeleton� thus 
sta�ilizing microtu�ules and preventing microtu�ule 
reorganization� towards disruption of kinetochore 
formation during mitosis [�9]. Proposed mechanisms 
conferring taxane resistance involve either microtu�ule 
mutations that prevent drug �inding or the cell itself 
pumps out the taxane through P­glycoprotein pumps 
[��]. Taxanes have �een used against other solid 
tumors such as �reast� lung� ovarian� and esopha­
geal cancers [��� ��]. Alternative approaches involve 
inducing or restoring the apoptotic pathways through 
a variety of other agents such as staurosporin� etopo­
side� and a new emerging class of apoptosis inducing 
agents� the death ligands such as TRAIL.
MECHANISMS OF APOPTOSIS 
REGULATION 
Apoptosis �programmed cell death� plays a critical 
role in regulating cell growth and tissue development. 
�ince loss of apoptosis leads to tumor initiation� 
growth� and progression [��]� exploitation of apoptosis 
mechanisms can lead to developing new anticancer 
strategies� that can effectively impair the tumorigenic 
process. Each pathway of apoptosis is activated �y dif­
ferent triggers such as cell­detachment �anoikis� mito­
chondrial signals �intrinsic pathway�� or death ligands 
�extrinsic pathway� �Figs. � and ��. 
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Fig. 1. Intrinsic and ER pathways of apoptosis. The intrin­
sic pathway of apoptosis activated �y various stimuli� leads 
to a down­regulation of anti­apoptotic BCL­� family mem�ers� 
allowing pro­apoptotic mem�ers to pertur� the mitochondria. 
Cytochrome c release from the mitochondria leads to APAF­� and 
pro­caspase­9 recruitment forming the apoptosome; cas­
pase­9 is then activated� cleaving downstream targets� such 
as executioner caspase­� and ­�. The ER stress pathway induces 
the activation of caspase­� or ­�� leading to caspase­�� activa­
tion� which then activates the intrinsic pathway of apoptosis 
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Fig. 2. TRAIL­mediated extrinsic pathway of apoptosis. Medi­
ated through the �inding of TRAIL to its cognate receptor� upon 
�inding the receptors oligomerize within the mem�rane. Fas 
associated death domain �FADD� is recruited� followed �y pro­
caspase­8 which is then processed into its active p�8 and 
p�� su�units which then can oligomerize into a heterotetramer 
A mechanism designed to protect against cellular 
metastasis is anoikis� which is an apoptosis pro­
gram that is induced upon the loss of critical protein 
interactions �etween the cell and the extracellular 
matrix. The major players and pathways involved with 
anoikis are integrin� focal adhesion� and growth fac­
tors �IGF­�� interactions as well as the JNK pathway� 
and caspase activation signaling events [��]. Anoikis 
plays a role in all tissue development and regenera­
tion and in preventing epithelial cell detachment and 
migration in normal and tumor cells [��]� including 
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shedding of colon epithelial cells [��] and mammary 
gland reduction [��� �8]. Anoikis is initiated when 
adherent cells detach from the �asement mem�rane� 
more specifically� the loss of integrin �either α� or β�� 
signaling with the focal adhesion points [�9]. Apoptotic 
pathways are activated upon cell detachment and 
loss of integrin signaling in normal cells; cancer cells 
develop resistance to anoikis through diverse mecha­
nisms such as over­coming the loss of focal adhesion 
kinase �FAK�� overexpression of talin �integrin partner/
focal adhesion player�� acquiring mutations in FAK 
that trigger anoikis inhi�itory mechanisms or navigat­
ing stimuli from the microenvironment signaling loss 
of apoptotic pathways [��]. 
The intrinsic pathway of apoptosis is under 
heavy regulation �y several different types of mo­
lecules that can �e separated into two main classes� 
anti­apoptotic proteins such as the XIAP �inhi�itors 
of apoptosis�� BCL­� family proteins such as BCL­�� 
BCL­xL or the pro­apoptotic proteins� which include 
BCL­� family mem�ers; BAX� BAD� BID� �MAC� and 
Dia�lo are activated through signaling events that 
lead to mitochondrial outer mem�rane permea�iliza­
tion �MOMP�. Cytochrome c is released� �inds with 
APAF­� and caspase­9 to form the apoptosome [��]. 
Upon apoptosome formation� caspase­9 �ecomes 
catalytically active and acts on downstream targets 
including caspase­� and ­� �Fig. �� [��]. Tumor cells 
can inactivate apoptotic signaling programs �y engag­
ing anti­apoptotic mechanisms involving the up­regu­
lation of apoptotic suppressors �Bcl­�� Bcl­xL� and/
or through the down­regulation of critical apoptosis in­
ducing players such as the caspase family �caspase­�� 
­�� ­�� ­8� ­9� ­��� ­��� [��]. Mechanisms that inhi�it 
the intrinsic pathway of apoptosis are interconnected 
with activities of the AKT �Fig. �� and NF­κB pathways. 
Therefore� activated AKT pathway inhi�its the intrin­
sic pathway of apoptosis as AKT signaling promotes 
BCL­� and BCL­xL activity while inhi�iting BAX and 
BAD players involved with inducing apoptosis [��]. 
Blocking BAX and BAD activity can prevent MOMP 
from opening� thus preventing cytochrome c release� 
and consequentially inhi�iting apoptosome forma­
tion. Another family of anti­apoptotic proteins that can 
inhi�it �oth the intrinsic and extrinsic pathways is the 
inhi�itors of apoptosis �IAP� which have two arms� the 
cIAP or X­linked IAP �XIAP�. The IAP family consists 
of E� ligases that can �lock apoptosome formation 
through �inding directly to APAF­� or caspase­9� thus 
inhi�iting caspase­9 activation [��]. XIAP also �ind 
directly to caspase­� preventing its activation� and 
in­addition to �locking activation XIAP can facilitate 
the transfer of u�iquitin� there�y tagging the caspases 
for degradation �y the ��� proteasome [��]. There 
are also mutations acquired in the pro­apoptotic ma­
chinery itself� the most nota�le mutations �eing those 
occurring in the caspase family. To that end� �rinvisula 
et al.� identified caspase­9β� a caspase­9 mutant that 
lacks the large active su�unit and esta�lished that 
caspase­9β acts in a dominant negative fashion pre­
venting caspase­� activation [��]. Moreover� Park and 
colleagues identified several gene polymorphisms 
that give rise to altered forms of caspase­9 that 
impair caspase­9 activity and there�y �lock apop­
tosis induction [�8]. Post­translational modification 
of caspase­9 phosphorylation at Thr ��9 mediated 
as a result of CDK­� and cyclin B in cell cycle [�9] also 
prevents caspase­9 recruitment to the apoptosome 
�locking caspase­9 activation. Regardless of how 
caspase­9 is modified� if this caspase fails to �e­
come active then the su�sequently executioner cas­
pase­�/­� activation is inhi�ited� ultimately impairing 
the intrinsic pathway of apoptosis activation [��� ��]. 
The extrinsic pathway �also referred to as the death 
receptor pathway� involves the induction of apoptosis 
through the activation of death receptors via death 
ligands such as tumor necrosis factor­α �TNF­α�� 
FA�L� and TRAIL [��]. While FA�L and TRAIL strictly 
activate the extrinsic pathway mediated apoptosis� 
TNF­α can play two different roles� although this mole­
cule is capa�le of inducing apoptosis� TNF­α is also 
capa�le of activating pro­survival pathway. TNF­acti­
vation impacts several critical cellular pathways some 
of which include cellular proliferation� differentiation� 
and apoptosis [��]. �pecifically� TNF­α �inding to its 
cognate receptor can lead to the formation of two 
separate complexes� complex � which can lead to the 
induction of either the NF­κB pathway �pro­survival� 
[��] or complex � which activates the apoptotic 
pathway mediated primarily through Fas associated 
death domain �FADD� and caspase­8 activation [��]. 
Complex � mediated NF­κB induction is initiated 
through the �inding of TNF­α to its cognate receptor 
TNFR­� which then leads to the recruitment of two 
adaptor proteins TNF receptor­associated protein 
with a death domain �TRADD� and receptor­interacting 
protein � �RIP�� [��]. Upon �inding of TRADD another 
adaptor molecule� TNF associated factor­� �TRAF�� 
followed �y the recruitment of cIAP �cellular inhi�itors 
of apoptosis�� as well as U�c� and U�c�� �E� u�iq­
uitin conjugating enzymes� [��] to form complex �. 
Once complex � is formed� TRAF� is phosphorylated 
�y PKC resulting in K�� link polyu�iquitination [�8] 
that leads to proteasomal degradation [�9]. TRAF�� 
cIAP� and U�c�� function in concert to facilitate 
K�� linked polyu�iquitination of RIP� [8�]. K�� linked 
polyu�iquitination of RIP­� leads to activation of Tak�/
TAB complex to activate the IKK complex [8�]. The 
IKK complex consists of several components� IKK α� 
IKK β� and IKK γ� this kinase complex phosphorylates 
the inhi�itor of kappa B molecule �IκB­α� [8�]. IκB α� 
is a �ound inhi�itor of NF­κB that functions to prevent 
nuclear import of NF­κB into the nucleus. Nuclear 
translocation of NF­κB results in �inding to its re­
spective DNA �inding sites and gene activation [8�]. 
NF­κB up­regulates several different gene types� 
such as inflammatory response pro­survival genes� 
BCL­� family� caspase­8 inhi�itor c­FLIP� cIAP and 
angiogenesis players and proliferation genes� cyclin 
D� and MYC [8�]. Interestingly enough� proteasome 
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inhi�ition can impede the NF­κB pathway as it prevents 
proteasome degradation of IκB­α thus leading to de­
creased activation of NF­κB [8�]. 
Apoptosis induction through complex � of the 
TNF­α pathway proceeds via depletion of c­FLIP and/
or c­IAP expression� as well RIP� kinase phosphoryla­
tion [8�� 8�]. Once phosphorylated� RIP�� FADD and 
initiator caspase­8 are recruited thus assem�ling com­
plex �. Once complex � is formed� caspase­8 is pro­
cessed and can then cleave its downstream targets� 
caspase­� and ­�� towards apoptosis execution [88]. 
Recent evidence identified the ripoptosome� a �mD 
apoptosis signaling complex composed of RIP­�� 
FADD� and caspase­8m as a key player in apoptosis 
activation [89]. This complex assem�les when cIAP 
expression levels are depleted� either through up­reg­
ulation of �MAC� a direct inhi�itor of cIAP� or through 
�MAC mimetics or other chemotherapeutics such 
as etoposide� which is a topoisomerase II inhi�itor 
used to treat solid tumors. In addition to inducing DNA 
�reaks� etoposide can down­regulate cIAPs [89�9�]. 
The a�ility to form this apoptosis inducing complex� 
can serve as a powerful tool for developing anti­
cancer strategies �ecause an agent �or com�ination 
of agents� could induce apoptosis� while �ypassing 
the normal requirements for apoptosis induction. 
Interestingly the ripoptosome triggers necroptopsis 
�programmed necrosis� mediated through RIP� sig­
naling [���]. 
The extrinsic pathway of apoptosis is a�rogated 
through several mechanisms� including the up­regula­
tion of the inhi�itors of apoptosis proteins such as cIAP 
or XIAP. Up­regulation of these inhi�itors of apopto­
sis molecules will drive the TNF­α pathway towards 
NF­κB activation in the same manner as descri�ed 
a�ove. Apart from inhi�ition �y the IAP family� recent 
data indicate that IL­�/�TAT� signaling can override 
apoptotic signals �y activating pro­survival proteins 
�BCL­�� BCL­xL� as well as cyclin D [9�]. TRAIL­ and 
FA�­mediated apoptosis pathways are very similar 
to one another in that these trimeric ligands �ind their 
specific cognate receptors towards apoptosis induc­
tion. TRAIL �inds to the DR �/DR� receptors which leads 
to receptor oligomerization in the plasma mem�rane� 
some groups suggest that these receptors oligomerize 
in the lipid rafts of the plasma mem�rane [9�]. Once 
the receptors oligomerize there is recruitment of adap­
tor protein FADD. FADD �inding to the TRAIL receptor 
leads to initiator caspase­8 recruitment to form the 
death inducing signaling complex �DI�C�. Following 
DI�C formation procaspase­8 �ecomes autocata­
lytically active� once active caspase­8 is processed 
into the active p�8 and p�� su�units via two cleavage 
events. Once processed the p�8 and p�� dimers 
can oligomerize with other p�8/p�� dimers to form 
active heterotetramers� that cleaves specific targets 
such as HDAC� [9�]� and executioner caspase­� and 
­� which fully induce the apoptotic response [9�]. 
Tumor cells utilize various mechanisms to inactivate 
the extrinsic pathway of apoptosis; that �e down­
regulation of death receptors or up­regulation of decoy 
receptors [9�]. For TRAIL� its cognate receptors con­
sist of death receptor­� or ­� �DR­�� ­��� as a protec­
tive measure� the cell also expresses decoy receptors 
Dcr� and Dcr� as an effort to prevent unintended 
apoptosis induction through TRAIL �inding to the 
death receptors [98]. In addition to receptor or decoy 
mediated inhi�ition� the extrinsic pathway is inhi�ited 
�y over­expression of BCL­�� BCL­xL� cIAP and XIAP 
anti­apoptotic proteins [99� ���]. �tudies in mouse 
models demonstrated that TRAIL targets cancer 
cells and not healthy non­neoplastic cells [���]. This 
specificity renders TRAIL a valua�le chemotherapeutic 
agent due to the limited side effects and TRAIL protein 
can �e synthesized via standard protein purification 
methods [��]. TRAIL C­terminal conjugation can ex­
tend TRAIL half­life �y �� hours allowing it to �e used 
for in vitro and in vivo experiments. For clinical trial 
and treatment applications companies� like Human 
Genome �ciences �Rockville MD� U�A� have gene­
rated TRAIL receptor activating anti�odies with the 
intent to extend TRAIL half­life. These companies were 
successful in generating TRAIL receptor anti�odies 
as evidenced �y several in vitro and in vivo studies that 
analyzed TRAIL anti�odies� mapatumuma� and lexa­
tumuma� indicating their a�ility to induce apoptosis 
[���� ���]. Additional pre­clinical studies have com­
�ined TRAIL with existing chemotherapeutic agents� 
including phytoshingosine �impacts sphingolipid me­
ta�olism� [���]� doxoru�icin [���]� docetaxel [���] 
and paclitaxel [���] all of which with much promise� 
suggesting that TRAIL should �e investigated further 
as a chemotherapeutic strategy. There is a clinical trial 
in progress involving the com�ination of TRAIL and 
VEGF inhi�itor� �evacizuma� �Clinical trial identifier� 
NCT����8����. 
CASPASES IN CONTROL OF APOPTOSIS 
Caspases are a family of cysteine proteases which 
contain cysteine residue at their active site and cleave 
their su�strate at position next to aspartate residue. 
A very unique family of enzymes which remain active 
right from early stages of em�ryonic development 
till the death of organism. The entire group of mam­
malian caspases is divided into three different groups 
on the �asis of their prodomains and specific func­
tion they play in the in several different pathways� 
including� inflammatory� development� and apoptotic 
pathways. Although each caspase serves a different 
purpose there are several similarities in cleavage� 
the proform is cleaved into a large catalytically ac­
tive su�unit and a small su�unit as shown for the 
critical apoptotic caspase­8. Caspase­� and ­� play 
a role in inflammation [��8� ��9]. The endoplasmic 
reticulum �ER� stress response pathways� unfolded 
protein response �UPR�� or ER associated degradation 
�ERAD� are mediated through caspase­�� eventu­
ally leading apoptosis induction through the intrinsic 
pathway. ER is a critical cellular organelle whose 
primary function is to ensure proteins are properly 
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folded �efore export into the Golgi apparatus [���]. 
The protein folding machinery consists of several 
components that work in concert to ensure proper 
protein folding. However� when the ER is overwhelmed 
with polypeptides that are incapa�le of �eing folded 
correctly� three sensors� IRE­�� PERK� and ATF� trig­
ger the UPR [���]. As high ER stress persists� CHOP 
expression is markedly increased� down­regulating the 
pro­survival BCL­� family mem�ers� BCL­� and BCL­
xL allowing for BAX and BAD expression and activity 
to increase [���]. Alternative intrinsic pathway induc­
tion mechanisms involve the activation of caspase­�� 
­�� and ­�� [���]� contri�uting to caspase­9 process­
ing either through disrupting the mitochondria [���] 
or through APAF­� independent mechanisms [���]. 
Caspase­� induces the intrinsic pathway of apoptosis 
either through Bid cleavage thus leading to intrinsic 
pathway activation via the opening of the MOMP re­
leasing cytochrome c facilitating apoptosome forma­
tion or through caspase­�� PIDD� and adaptor protein 
RAIDD �ind and form PIDDosome [���]. Compared 
to healthy cells� tumor cells have a marked increase 
in protein synthesis as well as an over­production 
of misfolded or unfolded protein in the ER� resulting 
in extremely high ER stress levels. Therefore treatment 
strategies focus on apoptosis induction via elevating 
ER stress using chemotherapeutics such as velcade 
[���]. Velcade is designed to �lock the ��� protea­
some and once inhi�ited� UPR response mechanisms 
�ecome impaired leading to apoptosis induction [��8]. 
To circumvent proteasome inhi�ition� cells activate 
lysosomal pathways as an alternate mechanism for 
protein clearance. Exploitation of this mechanism 
as an anti­cancer strategy involves the use of vel­
cade in com�ination with lysosomal inhi�itor� tu�acin 
�an HDAC� inhi�itor that �lock aggresome formation�� 
that results apoptosis [��9]. The major players involved 
with the intrinsic pathway of apoptosis induction� are 
cytochrome c� APAF­�� and caspase­9 which form the 
apoptosome. Caspase­9 is su�sequently processed 
into its active p�� and p�9 su�units [���] and capa�le 
of cleaving executioner caspase­�/­�. Cancer circum­
vents the intrinsic pathway activation �y engaging vari­
ous mechanisms� such as loss of caspase­9 activation 
via the involvement of the BCL­� family mem�ers� BCL­
�� BCL­xL or XIAP �inding� or �y �locking apoptosome 
formation through pro­survival signals� preventing the 
opening of the mitochondria and �locking the release 
of cytochrome c [���]. Of direct clinical significance 
is evidence that tumors from patients with colorectal� 
lung� or gastric cancer� har�or different point muta­
tions in caspase­9� that render it inactive and incapa�le 
of inducing apoptosis [���]. 
The mechanistic landscape of caspase activation 
during the tumor cellular demise� takes intriguing 
functional turns during cancer initiation and progres­
sion �Fig. ��. Executioner caspase­� and ­� �effector 
caspases� are processed into active su�units and re­
sponsi�le for the execution of the apoptosis program 
through the cleavage of caspase­activated DNase 
which then translocates to the nucleus and cleaves 
DNA [���]. Caspase­� propagates and amplifies the 
apoptosis signal through a loop that leads to cas­
pase­9 cleavage thus further propagating the apop­
totic cascade [���]. Loss of caspase­� expression pro­
motes tumorigenesis [���]� while caspase­� is down 
regulated in cancer [���]. Caspase­�� is an initiator 
caspase recruited to the DI�C like caspase­8 and is ca­
pa�le of inducing apoptosis in certain caspase­8 de­
ficient tumor cells [���] however� caspase­�� is not 
sufficient to induce apoptosis in the a�sence of cas­
pase­8 in other cancer types [��8]. 
Fig. 3. General cleavage events for critical apoptotic related 
caspases. Caspase­8 and ­�� are larger than other caspases 
�ecause they contain DED domains responsi�le for �inding 
to the DI�C complex
CASPASE-8 IN DEATH RECEPTOR 
INDEPENDENT AND DEPENDENT 
PATHWAYS
Intriguing new evidence supports a role for cas­
pase­8 in non­apoptotic signaling pathways. �tupack 
et al. ����9� reported that caspase­8 in neuro�las­
toma cell lines plays a role in mediating focal adhe­
sion complex formation and cellular migration [��9]. 
Earlier studies defined a pathway� similar to anoikis 
phenomenon� termed intergin mediated death [���]. 
Caspase­8 is phosphorylated on tyrosine residue 
�8� via �RC kinase and is associated with FAK and 
CNB� and upon its recruitment activates the calpain 
family of proteases that cleave talin [���]. �ignificantly 
enough� the N­terminal cleavage product of talin� 
the FERM� is an integrin �inding domain which facili­
tates cell migration [��9]� indirectly implicating cas­
pase­8 in mediating metastasis via the focal adhesion 
complex [��9]. Moreover� Ra��� a critical modulator 
of caspase­8 action in cell migration [���]� is function­
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ally involved in migration� either through lamellipodia 
formation [���]� β� integrin �inding� or through actin 
cytoskeleton [���].
�everal lines of evidence support the involvement 
of caspase­8 in EGF signaling pathways inducing 
ERK activation through the incorporation of cas­
pase­8 in �RC containing complexes. This work iden­
tified through a RXDLL motif found within the DED 
of caspase­8 pro­domain� this allows caspase­8 to as­
sociate with �RC although the data did not show any 
evidence that caspase­8 phosphorylation was required 
for �RC association and EGF pathway activation [���]. 
Caspase­8 as a critical player for extrinsic pathway 
activation has long �een considered a tumor sup­
pressor molecule. Indeed caspase­8 deficient cells 
are insensitive to death ligand stimulus and cannot 
induce apoptosis through the extrinsic pathway� thus 
facilitating tumorigenic transformation and conferring 
therapeutic resistance [���]. Human cancer cells 
regulate caspase­8 activity through a variety of mecha­
nisms� one mechanism is caspase­8 partial or whole 
gene deletion� [���] or gene methylation. For example� 
medullo�lastoma pediatric neuro�lastoma tumors 
down­regulate caspase­8 expression through methy­
lation of the caspase­8 promoter there�y inhi�iting 
caspase­8 transcription thus preventing protein trans­
lation and expression [��8]. �tudies involving a screen 
across multiple cancer types identified frame shift and 
missense mutations in caspase­8 [��9]� which altered 
amino acid compositions in the DED domain� a domain 
a�solutely critical for caspase­8 recruitment to the 
DI�C and initiating cleavage events [��9]. Moreover� 
mutations were found in the p�8 catalytically active 
su�unit and the p�� regions validation of the screen 
results revealed that most of the mutants severely 
diminished apoptosis induction in gastric carcinomas 
[��9]. Upon recruitment to the DI�C caspase­8 un­
dergoes two cleavage events� the first cleavage event 
occurs at aspartic acid residue �8� in the p�� su�unit� 
giving rise to the p��/�� intermediate which is �ound 
at the DI�C. This cleavage event is followed �y a se­
cond cleavage at aspartic acid residues ���� ��� which 
then release caspase­8 from the DI�C into the cy­
tosol �Fig. ��. Pioneering work �y Dr. Marcus Peter 
defined how the DI�C components were assem�led 
at the plasma mem�rane through TRAIL and/or FA� 
receptor and FADD palmitylation [���� ���]. Further 
studies provided evidence towards DI�C mediated 
caspase­8 processing [���� ���]. Additional studies 
focusing on DI�C formation �y Marcus Peter’s la� 
identified that c­FLIP was a specific inhi�itor of cas­
pase­8 DI�C recruitment and activation [���]. �u�se­
quent work identified c­FLIP isoforms that �lock gene 
induction as well as processing of caspase­8 [���]. 
Besides c­FLIP� XIAP and cIAP are also capa�le 
of �locking caspase­8 activation [���]. Emerging 
evidence �y two independent groups� Jin et al. [���]� 
and Peng et al. [��8]� provided new insights regard­
ing caspase­8 polyu�iquitination. Jin and colleagues 
provided evidence indicating that E� ligase CUL� me­
diated polyu�iquitination led to caspase­8 incorpora­
tion into an aggresome. Caspase­8 polyu�iquitination 
however in the context of EGR signaling� is mediated 
through R�K� activity [��8]� engaging two E� ligases� 
�iah� and PO�H� in prostate cancer cells [��9]� thus 
exerting a regulatory role on caspase­8 activity down­
stream of DI�C and caspase­8 processing [��9]. The 
com�ination of proteasome inhi�ition with TRAIL takes 
an all­lethal impact� as it induces apoptosis in TRAIL­
resistant prostate cancer cells in vitro and in vivo [��]. 
Moreover� com�ination of TRAIL and velcade leads 
to caspase­8 p�8 su�unit sta�ilization [��� ��� ���]� 
implicating caspase­8 degradation �eing controlled 
�y the ��� proteasome.
In summary� strategies to circumvent therapeutic 
resistance �y restoration of apoptotic pathways� utiliz­
ing single apoptosis inducing agents such as TRAIL� 
separately or in com�ination with other chemothera­
peutics� provide new promise in the clinical manage­
ment of cancer patients. These apoptosis inducing 
agents may also �e capa�le of inducing apoptosis� 
regardless of the tumor hormonal milieu and driven 
�y the cellular interactions with the tumor microenvi­
ronment. In that regard com�ination of proteasome 
inhi�itor and TRAIL is capa�le cleaving and activating 
caspase­8 in either androgen­dependent� or androgen 
independent prostate cancer �CRPC�. The clinical 
knowledge of microtu�ulin­targeted chemotherapy 
�taxanes� as the only effective treatment for CRPC� 
calls for the need to understand the mechanisms 
of action of this drug in order to augment its therapeu­
tic efficacy and overcome the therapeutic resistance 
to its antitumor actions in a large num�er of prostate 
cancer patients. Profiling the caspase activation status 
in response to taxane­�ased chemotherapy �in com­
�ination with apoptosis­driven agents� and in the 
context of cytoskeleton organization� provides excit­
ing new platforms for therapeutic optimization driving 
apoptosis to its full execution in a su�set of tumors and 
ultimately impacting patient survival.
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